Effect of Fluoroquinolone Treatment on Growth of and Toxin Production by Epidemic and Nonepidemic Clostridium difficile Strains in the Cecal Contents of Mice
Open Access
- 1 August 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (8) , 2674-2678
- https://doi.org/10.1128/aac.01582-06
Abstract
Several recent outbreaks of Clostridium difficile -associated disease (CDAD) have been attributed to the emergence of an epidemic strain with increased resistance to fluoroquinolone antibiotics. Some clinical studies have suggested that fluoroquinolones with enhanced antianaerobic activity (i.e., gatifloxacin and moxifloxacin) may have a greater propensity to induce CDAD than ciprofloxacin and levofloxacin do. We examined the effects of subcutaneous fluoroquinolone treatment on in vitro growth of and toxin production by epidemic and nonepidemic C. difficile isolates in cecal contents of mice and evaluated the potential for these agents to inhibit fluoroquinolone-susceptible isolates during treatment. When C. difficile isolates were inoculated into cecal contents collected 2 days after the final antibiotic dose, gatifloxacin and moxifloxacin promoted significantly more growth and toxin production than ciprofloxacin and levofloxacin did. During treatment, gatifloxacin and moxifloxacin inhibited growth of fluoroquinolone-susceptible but not fluoroquinolone-resistant isolates. Ciprofloxacin and levofloxacin promoted growth of C. difficile when administered at higher doses (i.e., 20 times the human dose in mg/kg of body weight), and levofloxacin inhibited growth of fluoroquinolone-susceptible, but not fluoroquinolone-resistant, C. difficile isolates when administered in combination with ceftriaxone. Thus, fluoroquinolones with enhanced antianaerobic activity (i.e., gatifloxacin and moxifloxacin) promoted C. difficile growth to a greater extent than did ciprofloxacin and levofloxacin in this model. However, our findings suggest that fluoroquinolones may exert selective pressure favoring the emergence of epidemic fluoroquinolone-resistant C. difficile strains by inhibiting fluoroquinolone-susceptible but not fluoroquinolone-resistant isolates during treatment and that agents such as levofloxacin or ciprofloxacin can exert such selective pressure when administered in combination with antibiotics that disrupt the anaerobic microflora.Keywords
This publication has 16 references indexed in Scilit:
- Moxifloxacin prophylaxis in neutropenic patientsJournal of Antimicrobial Chemotherapy, 2006
- Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study during an Epidemic in QuebecClinical Infectious Diseases, 2005
- Effect of Antibiotic Treatment on Growth of and Toxin Production by Clostridium difficile in the Cecal Contents of MiceAntimicrobial Agents and Chemotherapy, 2005
- A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone UseInfection Control & Hospital Epidemiology, 2005
- Clindamycin, Cephalosporins, Fluoroquinolones, andClostridium difficile–Associated Diarrhea: This Is an Antimicrobial Resistance ProblemClinical Infectious Diseases, 2004
- Effect of antimicrobial agents on the ecological balance of human microfloraThe Lancet Infectious Diseases, 2001
- Epidemics of Diarrhea Caused by a Clindamycin-Resistant Strain ofClostridium difficilein Four HospitalsNew England Journal of Medicine, 1999
- Ciprofloxacin and Clostridium difficile-associated diarrhoeaJournal of Antimicrobial Chemotherapy, 1992
- Evaluation of the predictive capability of an in-vitro model of colonisation resistance toClostridium difficileinfectionMicrobial Ecology in Health & Disease, 1988
- Intestinal -Lactamase Activity in Ampicillin-Induced, Clostridium difficile-Associated IleocecitisThe Journal of Infectious Diseases, 1983